HK1206624A1 - Brutons tyrosine kinase inhibitors for hematopoietic mobilization - Google Patents

Brutons tyrosine kinase inhibitors for hematopoietic mobilization

Info

Publication number
HK1206624A1
HK1206624A1 HK15107283.4A HK15107283A HK1206624A1 HK 1206624 A1 HK1206624 A1 HK 1206624A1 HK 15107283 A HK15107283 A HK 15107283A HK 1206624 A1 HK1206624 A1 HK 1206624A1
Authority
HK
Hong Kong
Prior art keywords
tyrosine kinase
kinase inhibitors
brutons tyrosine
mobilization
hematopoietic
Prior art date
Application number
HK15107283.4A
Other languages
English (en)
Chinese (zh)
Inventor
Raquel Izumi
Francisco Salva
Ahmed Hamdy
Original Assignee
Raquel Izumi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raquel Izumi filed Critical Raquel Izumi
Publication of HK1206624A1 publication Critical patent/HK1206624A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15107283.4A 2012-04-11 2015-07-30 Brutons tyrosine kinase inhibitors for hematopoietic mobilization HK1206624A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261622843P 2012-04-11 2012-04-11
PCT/US2013/036242 WO2013155347A1 (en) 2012-04-11 2013-04-11 Bruton's tyrosine kinase inhibitors for hematopoietic mobilization

Publications (1)

Publication Number Publication Date
HK1206624A1 true HK1206624A1 (en) 2016-01-15

Family

ID=48193277

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107283.4A HK1206624A1 (en) 2012-04-11 2015-07-30 Brutons tyrosine kinase inhibitors for hematopoietic mobilization

Country Status (5)

Country Link
US (1) US9522917B2 (xx)
EP (1) EP2836214B1 (xx)
ES (1) ES2681050T3 (xx)
HK (1) HK1206624A1 (xx)
WO (1) WO2013155347A1 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2015061751A1 (en) 2013-10-25 2015-04-30 Pharmacyclics, Inc. Methods of treating and preventing graft versus host disease
CN103694241A (zh) 2013-11-27 2014-04-02 苏州晶云药物科技有限公司 Pci-32765的新晶型a及其制备方法
US20150157634A1 (en) * 2013-12-02 2015-06-11 Pharmacyclics, Inc. Methods of treating and preventing alloantibody driven chronic graft versus host disease
WO2016024232A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
CZ201584A3 (cs) 2015-02-09 2016-08-17 Zentiva, K.S. Sůl Ibrutinib sulfátu
WO2016167236A1 (ja) 2015-04-13 2016-10-20 第一三共株式会社 Ｍｄｍ２阻害剤とｂｔｋ阻害剤との併用治療法
CN106588914B (zh) * 2015-10-16 2018-11-02 陈剑 具有取代吡啶并咪唑类衍生物，其制备及其在医药上的应用
CZ2016196A3 (cs) 2016-04-06 2017-10-18 Zentiva, K.S. Pevné formy Ibrutinibu
CZ2016276A3 (cs) 2016-05-11 2017-11-22 Zentiva, K.S. Pevné formy volné báze ibrutinibu
WO2018002958A1 (en) 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
CA3111126A1 (en) 2018-08-31 2020-03-05 Stichting Katholieke Universiteit Synergistic combinations of amino acid depletion agent sensitizers (aadas) and amino acid depletion agents (aada), and therapeutic methods of use thereof
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DE69625013T2 (de) 1995-09-18 2003-08-21 Toray Industries, Inc. Grundgewebe für Airbags, sein Herstellungsverfahren und dieses Gewebe enthaltender Airbag
US6908763B1 (en) 1997-08-22 2005-06-21 The Board Of Trustees Of The Leland Stanford Junior University Mammalian common lymphoid progenitor cell
US7979057B2 (en) 2000-10-06 2011-07-12 S.F. Ip Properties 62 Llc Third-party provider method and system
ES2781475T3 (es) * 2002-09-18 2020-09-02 Janssen Pharmaceuticals Inc Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
US7235623B2 (en) 2003-11-26 2007-06-26 Eastman Chemical Company Polyester compositions for calendering
US8252587B2 (en) 2004-10-25 2012-08-28 Celerant Therapeutics, Inc. Methods of expanding myeloid cell populations and uses thereof
US8383095B2 (en) 2006-02-14 2013-02-26 Cellerant Therapeutics, Inc. Methods and compositions for enhancing engraftment of hematopoietic stem cells
MX347525B (es) 2006-09-22 2017-04-27 Pharmacyclics Llc Inhibidores de tirosina cinasa de bruton.
LT2190991T (lt) * 2007-08-06 2020-02-10 Noxxon Pharma Ag Sdf-1 surišančios nukleorūgštys ir jų panaudojimas
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
US8383124B2 (en) * 2008-03-12 2013-02-26 Children's Hospital Medical Center Mobilization of hematopoietic stem cells
EP2268635B1 (en) * 2008-04-21 2015-06-10 Taigen Biotechnology Co., Ltd. Heterocyclic compounds
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
EP2575818A4 (en) * 2010-06-03 2013-11-06 Pharmacyclics Inc USE OF INHIBITORS OF BRUTON TYROSINE KINASE (BTK)
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization

Also Published As

Publication number Publication date
EP2836214B1 (en) 2018-06-27
EP2836214A1 (en) 2015-02-18
US20150086507A1 (en) 2015-03-26
WO2013155347A1 (en) 2013-10-17
US9522917B2 (en) 2016-12-20
ES2681050T3 (es) 2018-09-11

Similar Documents

Publication Publication Date Title
IL261282A (en) Furinone compounds as kinase inhibitors
IL277951A (en) Pyrimidinyls are tyrosine kinase inhibitors
HK1211293A1 (en) Brutons tyrosine kinase inhibitors
HK1210775A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
HK1208442A1 (en) Substituted pyrrolopyrimidinylamino-benzothiazolones as mknk kinase inhibitors mknk
HK1212689A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
HK1215253A1 (zh) 作為激酶抑制劑的吡咯並嘧啶化合物
HK1206624A1 (en) Brutons tyrosine kinase inhibitors for hematopoietic mobilization
SI2710005T1 (sl) Zaviralci tirozinske kinaze
HK1194381A1 (en) Inhibitors of brutons tyrosine kinase
HK1197060A1 (en) Inhibitors of brutons tyrosine kinase
HK1211578A1 (en) Amidoimidazopyridazines as mknk-1 kinase inhibitors mknk-1
HK1210779A1 (en) Inhibitors of brutons tyrosine kinase
HK1210461A1 (en) Inhibitors of brutons tyrosine kinase
GB201211310D0 (en) CSF-1R kinase inhibitors
EP2934525A4 (en) THIAZOLSUBSTITUTED AMINOPYRIDINE AS MILTSTYROSINKINASE INHIBITOR
EP2988744A4 (en) THIAZOLE SUBSTITUTED AMINOHETEROARYL COMPOUNDS TYLOSINE KINASE SPLENIC INHIBITORS
PL2634185T3 (pl) Inhibitory kinazy TYK2
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
HK1200816A1 (en) Inhibitors of brutons tyrosine kinase
EP2903970A4 (en) SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
HK1215855A1 (zh) 酪氨酸蛋白激酶抑制劑
EP2968331A4 (en) PYRROLOPYRIMIDINE COMPOUNDS AS KINASEINHIBITORS
HK1209316A1 (en) Substituted picolinamide kinase inhibitors